Literature DB >> 11228258

Establishment of an in vivo model for pediatric Ewing tumors by transplantation into NOD/scid mice.

J Vormoor1, G Baersch, S Decker, M Hotfilder, K L Schäfer, L Pelken, C Rübe, F Van Valen, H Jürgens, B Dockhorn-Dworniczak.   

Abstract

Ewing tumors are a clinically heterogeneous group of childhood sarcomas that represent a paradigm for understanding solid tumor biology, as they are the first group of sarcomas for which a chromosome translocation has been characterized at the molecular level. However, the biologic organization of the tumor, especially the processes that govern proliferation, differentiation, and metastasis of primitive tumor stem cells is poorly understood. Therefore, to develop a biologically relevant in vivo model, five different Ewing tumor cell lines and primary tumor cells from three patients were transplanted into immune-deficient mice via intravenous injection. NOD/scid mice that carry a complex immune deficiency and thus nearly completely lack the ability to reject human cells were used as recipients. Overall, 26 of 52 mice (50%) transplanted with VH-64, WE-68, CADO-ES1, TC-71, and RM-82 cells and 4 of 10 mice (40%) transplanted with primary tumor cells engrafted. Moreover, primary cells that did not grow in vitro proliferated in mice. The pattern of metastasis was similar to that in patients with frequent metastases in lungs (62%), bone marrow (30%), and bone (23%). Using limiting dilution experiments, the frequency of the engraftment unit was estimated at 1 Ewing tumor-initiating cell in 3 x 10(5) VH-64 cells. These data demonstrate that we have been able to establish an in vivo model that recapitulates many aspects of growth and progression of human Ewing tumors. For the first time, this model provides the opportunity to identify and characterize primitive in vivo clonogenic solid tumor stem cells. This model will, therefore, be instrumental in studying many aspects of tumor cell biology, including organ-selective metastasis and tumor angiogenesis.

Entities:  

Mesh:

Year:  2001        PMID: 11228258     DOI: 10.1203/00006450-200103000-00006

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  14 in total

1.  In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis.

Authors:  Sung-Hyeok Hong; Jason U Tilan; Susana Galli; Rachel Acree; Katherine Connors; Akanksha Mahajan; Larissa Wietlisbach; Taylor Polk; Ewa Izycka-Swieszewska; Yi-Chien Lee; Luciane R Cavalli; Olga C Rodriguez; Chris Albanese; Joanna B Kitlinska
Journal:  J Vis Exp       Date:  2016-12-09       Impact factor: 1.355

2.  New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination.

Authors:  Lan G Coffman; Daniela Burgos-Ojeda; Rong Wu; Kathleen Cho; Shoumei Bai; Ronald J Buckanovich
Journal:  Transl Res       Date:  2016-03-30       Impact factor: 7.012

Review 3.  Animal Models of Bone Metastasis.

Authors:  J K Simmons; B E Hildreth; W Supsavhad; S M Elshafae; B B Hassan; W P Dirksen; R E Toribio; T J Rosol
Journal:  Vet Pathol       Date:  2015-05-28       Impact factor: 2.221

4.  Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target.

Authors:  Wesley Hsu; Ahmed Mohyeldin; Sagar R Shah; Colette M ap Rhys; Lakesha F Johnson; Neda I Sedora-Roman; Thomas A Kosztowski; Ola A Awad; Edward F McCarthy; David M Loeb; Jean-Paul Wolinsky; Ziya L Gokaslan; Alfredo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2011-06-24       Impact factor: 5.115

5.  Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway.

Authors:  S Kamura; Y Matsumoto; J-I Fukushi; T Fujiwara; K Iida; Y Okada; Y Iwamoto
Journal:  Br J Cancer       Date:  2010-07-06       Impact factor: 7.640

6.  Successful high-resolution animal positron emission tomography of human Ewing tumours and their metastases in a murine xenograft model.

Authors:  Christiane Franzius; Marc Hotfilder; Christopher Poremba; Sven Hermann; Klaus Schäfers; Helmut Erich Gabbert; Heribert Jürgens; Otmar Schober; Michael Schäfers; Josef Vormoor
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-29       Impact factor: 10.057

7.  PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death.

Authors:  M Hotfilder; P Sondermann; A Senss; F van Valen; H Jürgens; J Vormoor
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

8.  Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models.

Authors:  Eva Rettinger; Vida Meyer; Hermann Kreyenberg; Andreas Volk; Selim Kuçi; Andre Willasch; Ewa Koscielniak; Simone Fulda; Winfried S Wels; Halvard Boenig; Thomas Klingebiel; Peter Bader
Journal:  Front Oncol       Date:  2012-04-09       Impact factor: 6.244

9.  The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.

Authors:  S Kailayangiri; B Altvater; J Meltzer; S Pscherer; A Luecke; C Dierkes; U Titze; K Leuchte; S Landmeier; M Hotfilder; U Dirksen; J Hardes; G Gosheger; H Juergens; C Rossig
Journal:  Br J Cancer       Date:  2012-02-28       Impact factor: 7.640

10.  Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line.

Authors:  Joseph B Moore; David M Loeb; Kyung U Hong; Poul H Sorensen; Timothy J Triche; David W Lee; Michael I Barbato; Robert J Arceci
Journal:  Front Cell Dev Biol       Date:  2015-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.